An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumor, Lymphoma

In brief

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Key facts

Study ID

NCT04186637

Run by

Alpine Immune Sciences, Inc.

People needed

62

Starts

2020-06-02

Expected to finish

2023-02-28

Last updated by the study team

2023-06-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site (004) — Scottsdale, Arizona, United States
• Investigational Site (003) — New Haven, Connecticut, United States
• Investigational Site (007) — Lafayette, Indiana, United States
• Investigational Site (006) — Louisville, Kentucky, United States
• Investigational Site (001) — Grand Rapids, Michigan, United States
• Investigational Site (009) — Portland, Oregon, United States
• Investigational Site (008) — Pittsburgh, Pennsylvania, United States
• Investigational Site (102) — Perth, Nedlands, Australia
• Investigational Site (101) — Melbourne, Victoria, Australia
• Investigational Site (103) — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.